Opinion · 29 Dec 2025
Conference abstractPublished 15 Apr 2022
New Technology based on Fiber Optic Nanogold-Linked Immunosorbent Assay for Rapid Glial Fibrillary Acidic Protein (GFAP) determination in Stroke
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In acute stroke, biomarker can not only differentiate true stroke patients from stoke mimicking conditions but also distinguish the difference between ischemic stroke (IS) and intracerebral hemorrhage (ICH). One of the stroke biomarkers, glial fibrillary acidic protein (GFAP) in acute stroke has been studied extensively in recent years. Several studies demonstrated a rapid increase to GFAP in blood samples of ICH patients compared to slow release in ischemic stroke. As the concentration of GFAP in blood is low, the detection is challenging. In this research, a rapid, high analytical sensitivity and selectivity based on fiber optic nanogoldlinked immunosorbent assay (FONLISA) technology is developed. The technology is based on the interaction of an analyte with a surface-immobilized capture antibody and a gold nanoparticle-labeled detection antibody to form a sandwich-like complex on a fiber core surface. The LOD for GFAP is 2.81 fg/mL with the linear dynamic range from 10 fg/mL to 1 ng/mL. On clinical GFAP detection with serum samples, totally 10 positive and 3 negative samples which checked by CT method are used. For ten positive samples, results from the FONLISA method are highly correlated (correlation coefficient, R = 0.98) with that from the ELISA method. For three negative samples, ELISA has one false-positive result, leading to a diagnostic specificity of 75%, while the specificity for FONLISA is 100%. In addition, the positive predictive value and test efficiency are 90.9% and 92.3% for ELISA, respectively, and 100% and 100% for FONLISA, respectively. The FONLISA method has advantages of short analysis time (about 15 min), high analytical sensitivity, good selectivity, inexpensive sensor chips, and also avoiding invasive procedures. We expect the immunosensor could be applicable to the point-of-care-testing (POCT) for diagnosis of GFAP in a patient-friendly manner.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Research & Reviews: Neuroscience.
Review article · 29 Dec 2025
Psychiatric Neuroscience: Bridging Brain Function and Mental Disorders
Perspective · 29 Dec 2025
Psychiatric Neurobiology: Bridging Brain Circuits, Molecular Pathways, and the Future of Mental Health Care
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalResearch & Reviews: Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Ting-Chou Chang”